Search Results - "Vladimirov, A. S."

Refine Results
  1. 1
  2. 2
  3. 3

    Current strategy in the treatment of calcium pyrophosphate crystal deposition disease by Vladimirov, S. A., Eliseev, M. S.

    “…The paper considers currently available drugs used to treat calcium pyrophosphate crystal deposition disease. It discusses the advantages and disadvantages of…”
    Get full text
    Journal Article
  4. 4

    USE OF METHOTREXATE IN PATIENTS WITH CALCIUM PYROPHOSPHATE CRYSTAL DEPOSITION DISEASE by Eliseev, M. S., Vladimirov, S. A., Nasonov, E. L.

    “…Objective: to compare the efficacy of methotrexate (MTX) and colchicine in patients with chronic arthritis in calcium pyrophosphate crystal deposition disease…”
    Get full text
    Journal Article
  5. 5

    Febuxostat in the therapy of gout: from theory to practice by Ilyinykh, E. V., Vladimirov, S. A., Eliseev, M. S.

    Published in Sovremennai͡a︡ revmatologii͡a (01-01-2018)
    “…Gout is a chronic disease that requires permanent urate-lowering therapy. Allopurinol is the gold standard of this therapy. The novel drug febuxostat, a…”
    Get full text
    Journal Article
  6. 6

    Production characteristics of bacteria and phytoplankton in the Sea of Okhotsk and Bering Sea during spring–summer by Zakharkov, S. P., Vladimirov, A. S., Shtraikhert, E. A., Shi, X., Gladkich, R. V., Buzoleva, L. S.

    Published in Microbiology (New York) (01-05-2017)
    “…Production parameters for bacterioplankton were assessed during the spring–summer period in the western parts of the Sea of Okhotsk and the Bering Sea, as well…”
    Get full text
    Journal Article
  7. 7

    THE PREVALENCE AND CLINICAL FEATURES OF GOUT AND CALCIUM PYROPHOSPHATE DEPOSITION DISEASE IN PATIENTS WITH ACUTE ARTHRITIS by Eliseev, M. S., Vladimirov, S. A.

    “…Objective: to study the rate of gout and calcium pyrophosphate deposition disease (CPDD) and to provide their clinical characteristics in patients with acute…”
    Get full text
    Journal Article
  8. 8

    Assessment of cardiovascular risk from the use of an interleukin-1 inhibitor in patients with severe tophaceous gout by Eliseev, M. S., Zhelyabina, O. V., Markelova, E. I., Novikova, D. S., Vladimirov, S. A., Korsakova, Yu. O., Aleksandrova, E. N., Novikov, A. A., Nasonov, E. L.

    Published in Sovremennai͡a︡ revmatologii͡a (01-03-2016)
    “…It is suggested that interleukin (IL)-1β inhibition may promote a reduction in the risk of cardiovascular diseases; however, the mechanism of this impact has…”
    Get full text
    Journal Article
  9. 9

    OSTEOPOROSIS IN CALCIUM PYROPHOSPHATE CRYSTAL DEPOSITION DISEASE by Vladimirov, S A, Kudayeva, F M, Barskova, Viktoria Geogiyevna

    “…Objective: to study the incidence of osteoporosis (OP) in patients with calcium pyrophosphate crystal deposition disease (CPCDD). Subjects and methods. Eighty…”
    Get full text
    Journal Article
  10. 10

    Modeling electromigration and the void nucleation in thin-film interconnects of integrated circuits by Goldstein, R V, Sarychev, ME, Shirabaikin, D B, Vladimirov, A S, Zhitnikov, YuV

    Published in International journal of fracture (01-05-2001)
    “…The modern tendency for increasing the productivity of microelectronic devices at the expense of the size shrinkage and the development of densely packed…”
    Get full text
    Journal Article
  11. 11

    Use of meloxicam (Amelotex®) in patients with chronic gout to prevent by M S Eliseyev, S A Vladimirov

    Published in Sovremennai͡a︡ revmatologii͡a (17-12-2011)
    “…The paper presents the results of a trial of the efficacy and safety of the nonsteroidal anti-inflammatory drug Amelotex® (meloxicam) used to prevent episodes…”
    Get full text
    Journal Article
  12. 12

    THE CLINICAL MANIFESTATIONS OF CALCIUM PYROPHOSPHATE CRYSTAL DEPOSITION DISEASE by Kudaeva, F. M., Vladimirov, S. A., Eliseev, M. S., Volkov, A. V., Severinova, M. V., Barskova, V. G.

    “…Objective: to provide the clinical characteristics of joint injury in patients with calcium pyrophosphate crystal (CPC) deposition disease.Subjects and…”
    Get full text
    Journal Article
  13. 13
  14. 14

    Use of meloxicam (Amelotex®) in patients with pyrophosphate arthropathy by Maksim Sergeevich Eliseev, S A Vladimirov, Maksim Sergeyevich Eliseyev

    Published in Sovremennai͡a︡ revmatologii͡a (16-09-2011)
    “…The paper presents the results of a trial of the efficacy and safety of the nonsteroidal anti-inflammatory drug Amelotex® (international nonproprietary name…”
    Get full text
    Journal Article
  15. 15

    Use of meloxicam (amelotex®) in patients with gonarthrosis by Maksim Sergeevich Eliseev, S A Vladimirov, Maksim Sergeyevich Eliseyev

    Published in Sovremennai͡a︡ revmatologii͡a (14-06-2011)
    “…The paper presents the results of a trial of the efficacy and safety of the nonsteroidal anti-inflammatory drug amelotex® (meloxicam) in patients with…”
    Get full text
    Journal Article
  16. 16
  17. 17
  18. 18

    Rheumatic manifestations of endocrine diseases: skeletal diseases in hypoparathyroidism by Barskova, Viktoria Georgiyevna, Vladimirov, S A, Bochkova, A G, Kudaeva, F M, Smirnov, A V, Bozhyeva, L A, Nasonov, E L

    Published in Sovremennai͡a︡ revmatologii͡a (14-10-2013)
    “…Parathyroid diseases cause serious musculoskeletal problems. The major function of parathyroid hormone (PTH) is to regulate calcium levels in the body, which…”
    Get full text
    Journal Article
  19. 19

    Osteonecrosis. Part 2. The clinical picture and diagnosis of avascular necrosis by Barskova, V G, Ilyinykh, Ekaterina Valeriyevna, Smirnov, A V, Vladimirov, S A, Mirovich, O V, Bozhyeva, L A, Nasonov, E L

    Published in Sovremennai͡a︡ revmatologii͡a (15-06-2013)
    “…The paper describes the major clinical manifestations of osteonecrosis (ON), considers methods for its radiodiagnosis, and characterizes changes depending on…”
    Get full text
    Journal Article
  20. 20

    USE OF INJECTABLE MELOXICAM (AMELOTEX®) FORMULATION IN PATIENTS WITH GONARTHROSIS by M S Eliseyev, M S Barskova, S A Vladimirov

    Published in Sovremennai͡a︡ revmatologii͡a (09-09-2009)
    “…The paper presents the results of a study of the efficiency and safety of using the nonsteroidal anti-inflammatory drug Amelotex® (international nonproprietary…”
    Get full text
    Journal Article